provides a protective environment to support the …
Post on 27-Feb-2022
1 Views
Preview:
TRANSCRIPT
PROVIDES A PROTECTIVE ENVIRONMENT TO SUPPORT THE HEALING CASCADE
• Derived from Human Umbilical Cord
• Comprised of an Extracellular Matrix of Hyaluronic Acid and Collagen
• Contains 250+ Regulatory Proteins1-2
EC151.001
Hyaluronic Acid Hydrates and Reinforces Collagen
Hyaluronic Acid
Collagen
2 cm x 3 cm Expands to 12 cm2
NEW SIZE!1 cm x 2 cm NOW AVAILABLE
Hyaluronic Acid (HA) can hold up to 1000 times its weight in water. As a primary component in the umbilical cord, natural HA hydrates, forming a reinforced matrix to support the wound healing cascade.5-6
Role of Hyaluronic Acid in Wounds
The ONLY CLINICALLY PROVEN Expandable Dehydrated Human Umbilical Cord Allograft3-4
Patents and patents pending see: www.mimedx.com/patents. EPICORD, PURION, SMR2T, and MIMEDX are trademarks of MIMEDX Group, Inc. ©2021 MIMEDX Group, Inc. All Rights Reserved. www.mimedx.com EC151.001
Patient Insurance Verification Team:855.882.8480
Clinical Use Examples• Smaller, deeper wounds• Thick graft allows for
suturing to keep the graft in place
• All EPICORD configurations conform to uneven surfaces
• EPICORD Expandable 2 cm x 3 cm expands to 12 cm2
Product Advantages• EPICORD RCT Level I Data*• SMR2TTM Technology• PURION Process• Terminal Sterilization• Easy to Apply• Room Temperature Storage• 5-year shelf life
866.477.4219 • customerservice@mimedx.com
*Identified as low risk-of-bias RCT in 2020 Skin Substitute Technical Assessment by Agency for Healthcare Research and Quality
A multicentre prospective randomised controlled comparative parallel study of dehydrated human umbilical cord (EPICORD) allograft for the treatment of DFUs7
Wound Closure Rates at 12 Weeks in Diabetic Foot Ulcer (DFU) Patients with EPICORD vs. Standard Care7
ITEM # SPECIFICATIONSAREA
WITHOUT EXPANSION
PREDICTED EXPANSION
DIMENSIONSQ CODE
EC-5120 EPICORD 1 cm x 2 cm 2 cm2 N/A Q4187
EC-5230 EPICORD 2 cm x 3 cm 6 cm2 N/A Q4187
EC-5350 EPICORD 3 cm x 5 cm 15 cm2 N/A Q4187
EX-5230EPICORD
EXPANDABLE 2 cm x 3 cm
6 cm2 12 cm2 (4 cm x 3 cm) Q4187
NEW SIZE
Intent-to-Treat With Adequate DebridementPer-Protocol (PP)
n=134Intent-to-Treat (ITT)
n=155 n=107100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%Control (SC) Control (SC) Control (SC)
n=86 n=67n=48 n=40n=54EPICORD + SC EPICORD + SC EPICORD + SC
n=101
81%
54%
70%
48%
p = 0.0089
p = 0.0013
p < 0.000196%
65% Additional Kaplan-Meier analysis on the ITT population showed subjects treated with EPICORD had a superior wound closure trajectory at 12 weeks compared to Control (p=0.0152)
EPICORD Configurations
REFERENCES 1. MM-RD-00086, Proteome Characterization of PURION Processed Dehydrated Human Amnion Chorion Membrane (dHACM) and PURION Plus Processed Dehydrated Human Umbilical Cord (dHUC) Allografts. 2. Bullard JD, Lei J, Lim JJ, Massee M, Fallon AM, Koob TJ. Evaluation of dehydrated human umbilical cord biological properties for wound care and soft tissue healing. J Biomed Mater Res B Appl Biomater. 2019;107(4):1035-1046. 3. ECX121.001, MIMEDX Case Study, Mixed Venous and Arterial RLE Ulcer Treated with EPICORD EXPANDABLE 4. ECX117.001, MIMEDX Case Study, The Use of EPICORD in Patients With Chronic Wounds and Concurrent Comorbidities 5. Sakamoto T, Ono H, Saito Y. Nihon Sanka. Electron microscopic histochemical studies on the localization of hyaluronic acid in Wharton’s jelly of the human umbilical cord. Nihon Sanka Fujinka Gakkai Zasshi. 1996;48(7):501-507. 6. Sobolewski K, Bańkowski E, Chyczewski L, Jaworski S. Collagen and glycosaminoglycans of Wharton’s jelly. Biol Neonate. 1997;71(1):11-21. 7. Tettelbach W, Cazzell S, Sigal F, et al. A multicentre prospective randomised controlled comparative parallel study of dehydrated human umbilical cord (EpiCord) allograft for the treatment of diabetic foot ulcers. Int Wound J. 2019;16(1):122-130.
EC-5120 EC-5230
EC-5350
EX-5230
NEW SIZE
2 cm x 3 cm expands to 12 cm2
Closu
re W
ithin
12 W
eeks
top related